International Patent: USE OF COMBINATION OF HYPOXIA-INDUCIBLE FACTOR-PROLYL HYDROXYLASE INHIBITOR (HIF-PHI) AND ERYTHROID MATURATION AGENT IN RARE ANEMIAS

GENEVA, Oct. 22 -- KIND PHARMACEUTICALS CO., LTD. filed a patent application (CN2026/089671) for “USE OF COMBINATION OF HYPOXIA-INDUCIBLE FACTOR-PROLYL HYDROXYLASE INHIBITOR (HIF-PHI) AND ERYTHROID MATURATION AGENT IN RARE ANEMIAS”. With publication no. WO/2026/219079, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: A61K 45/00

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....